Replies to post #278 on Novocure Ltd (NVCR)

[SkyLimit2022]

jondoeuk,

Your information is incorrect about the DCVax-L cell-based platform technology. You need to seek better sources.

While I support the DCVax-L technology as an investor, I also hope for the success of NVCR’s technology, PD1 blockade, and various combo therapies.

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171959537

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172099186